Opinion|Videos|March 12, 2024

Treatment Decisions for Favorable Risk RCC

Author(s)Elizabeth Plimack, MD, Benjamin L. Maughan, MD, PharmD, Martin H. Voss, MD

The panel discusses long-term data showing more limited benefit of IO-IO therapy versus TKI regimens for favorable risk RCC patients and implications for their risk-adapted treatment approach.

Episodes in this series

EP. 1 Long Term Follow Up Data From Checkmate 214 on Nivolumab Plus Ipilimumab in First Line Clear Cell RCC

EP. 1 Long Term Follow Up Data From Checkmate 214 on Nivolumab Plus Ipilimumab in First Line Clear Cell RCC

EP. 2 Subgroup Analysis from CLEAR Trial: Efficacy Outcomes by Baseline Tumor Size in Treatment of Metastatic Clear Cell RCC

EP. 2 Subgroup Analysis from CLEAR Trial: Efficacy Outcomes by Baseline Tumor Size in Treatment of Metastatic Clear Cell RCC

EP. 3 Network Meta-Analysis Comparing Efficacy of Lenvatinib Plus Pembrolizumab to Other First Line Treatments for Metastatic Clear Cell RCC

EP. 3 Network Meta-Analysis Comparing Efficacy of Lenvatinib Plus Pembrolizumab to Other First Line Treatments for Metastatic Clear Cell RCC

EP. 4 Frontline Treatment Approaches for Advanced Clear Cell RCC

EP. 4 Frontline Treatment Approaches for Advanced Clear Cell RCC

EP. 5 Treatment Decisions for Favorable Risk RCC

EP. 5 Treatment Decisions for Favorable Risk RCC

EP. 6 Managing Immune-Related Toxicities with Frontline RCC Therapies

EP. 6 Managing Immune-Related Toxicities with Frontline RCC Therapies

EP. 7 Treating Patients with RCC and Brain, Liver, or Bone Metastases

EP. 7 Treating Patients with RCC and Brain, Liver, or Bone Metastases

EP. 8 Frontline Therapy for Patients With Non-Clear Cell RCC

EP. 8 Frontline Therapy for Patients With Non-Clear Cell RCC

EP. 9 Non-Clear Cell RCC: Key Learnings and Future Research Directions

EP. 9 Non-Clear Cell RCC: Key Learnings and Future Research Directions

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Bladder-sparing options for BCG-unresponsive non-muscle invasive bladder cancer have transformed since 2020, according to Saum Ghodoussipour, MD.

September 14th, 2026

Rethinking BCG Failure and The Bladder-Sparing Boom in NMIBC

Bladder-sparing options for BCG-unresponsive non-muscle invasive bladder cancer have transformed since 2020, according to Saum Ghodoussipour, MD.

Trending on CancerNetwork

IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma

SOHO 2026: Key Updates Across the Multiple Myeloma Continuum

Secondary T-Cell Malignancies: Identifying and Counseling After CAR T-Cell Therapy

PALOMA-2 Shows Improved Survival vs Historical IV Amivantamab Data

WCLC 2026: How Will The Small Cell Lung Cancer Paradigm Change?